AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23908179 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct, objective measures of cone structure
Number of subjects: 26
Study 23908489 — intervention group
Group type: EXPERIMENTAL
Intervention: rHMPV-SHs
Number of subjects: 21
Study 23909727 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (PUFA) added to parenteral nutrition
Number of subjects: 80
Study 23909727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no omega-3 PUFA)
Number of subjects: 80
Study 23909991 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 161
Study 23909991 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 161
Study 23909991 — intervention group
Group type: COMPARATOR
Intervention: IVF and ICSI
Number of subjects: 161
Study 23911539 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS method for quantitation of chloroformate-derivatised amino acids, polyamines, and dipeptides
Number of subjects: 332
Study 23911539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa cell extract study
Number of subjects: 332
Study 23911539 — intervention group
Group type: EXPERIMENTAL
Intervention: Human urine study
Number of subjects: 332
Study 23911702 — intervention group
Group type: COMPARATOR
Intervention: CD45-high group (CD45 expression above the 75th percentile)
Number of subjects: 1065
Study 23911702 — intervention group
Group type: COMPARATOR
Intervention: CD45-high group
Number of subjects: 1065
Study 23912473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (PR; 50-250 mg twice daily)
Number of subjects: 63
Study 23912473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Number of subjects: 63
Study 23912473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol treatment
Number of subjects: 63
Study 23912587 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with whole leukemia cells (up to 6 vaccines initiated between days 30 and 45 after transplantation)
Number of subjects: 22
Study 23912587 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with whole leukemia cells
Number of subjects: 22
Study 23912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory strategies tested on the graft ex vivo during islet culture and/or on the graft site in vivo early after islet infusion.
Number of subjects: 0
Study 23912763 — intervention group
Group type: COMPARATOR
Intervention: Not available.
Number of subjects: 0
Study 23913461 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Pd/Pa ratio (≥ 0.9)
Number of subjects: 35
Study 23913461 — intervention group
Group type: COMPARATOR
Intervention: Abnormal Pd/Pa ratio (< 0.9)
Number of subjects: 35
Study 23913461 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal rFFR (≥ 0.8)
Number of subjects: 35
Study 23913461 — intervention group
Group type: COMPARATOR
Intervention: Abnormal rFFR (< 0.8)
Number of subjects: 35
Study 23913470 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat and niacinamide
Number of subjects: 24
Study 23915179 — intervention group
Group type: EXPERIMENTAL
Intervention: LWWCOPD programme for pulmonary rehabilitation
Number of subjects: 57
Study 23915500 — intervention group
Group type: EXPERIMENTAL
Intervention: AA homozygotes of rs2906569 (minor allele G, alternate allele A) at intron 1
Number of subjects: 1111
Study 23915500 — intervention group
Group type: EXPERIMENTAL
Intervention: CC homozygotes of rs2301963 (minor allele A, alternate allele C) at exon 3
Number of subjects: 1111
Study 23915500 — intervention group
Group type: COMPARATOR
Intervention: Combined frequency of rare missense variants
Number of subjects: 1111
Study 23916058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body support group for patients with all cancer types
Number of subjects: 0
Study 23916058 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual interventions incorporating spiritual values
Number of subjects: 0
Study 23916058 — intervention group
Group type: COMPARATOR
Intervention: Support through religious communities
Number of subjects: 0
Study 23916583 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 65
Study 23916692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ultrasmall superparamagnetic particles of iron oxide (USPIO) MRI and diffusion-weighted (DW) MRI
Number of subjects: 75
Study 23917460 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP phenotyping cocktail (50 mg tramadol, 20 mg omeprazole, 25 mg losartan, 200 mg caffeine) administered as a single oral dose.
Number of subjects: 22
Study 23918740 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality (PSQI > 5)
Number of subjects: 268
Study 23918740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smokers
Number of subjects: 268
Study 23918740 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with poor sleep quality
Number of subjects: 268
Study 23918740 — intervention group
Group type: COMPARATOR
Intervention: Good sleep quality (PSQI ≤ 5)
Number of subjects: 268
Study 23918838 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 212
Study 23918838 — intervention group
Group type: EXPERIMENTAL
Intervention: HR75%, HR80%, HR85%, HRKarv0.6, HRKarv0.7, HRKarv0.8
Number of subjects: 212
Study 23918838 — intervention group
Group type: COMPARATOR
Intervention: HRKarv0.7 or HR85%
Number of subjects: 212
Study 23918838 — intervention group
Group type: EXPERIMENTAL
Intervention: HRKarv0.6 or HR80%
Number of subjects: 212
Study 23919738 — intervention group
Group type: EXPERIMENTAL
Intervention: RESQ-7 (Reflux Symptom Questionnaire 7-day recall)
Number of subjects: 0
Study 23920034 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass liner (DJBL)
Number of subjects: 17
Study 23921069 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity inspiratory muscle training (≥50% of Pi,max)
Number of subjects: 170
Study 23921069 — intervention group
Group type: COMPARATOR
Intervention: Low intensity inspiratory muscle training (≤10% of Pi,max)
Number of subjects: 170
Study 23921878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra low-dose OCP (1.0 mg norethindrone acetate and 10 micrograms ethinyl E2)
Number of subjects: 1660
Study 23922111 — intervention group
Group type: EXPERIMENTAL
Intervention: High tumour expression of miRNA-126
Number of subjects: 230
Study 23922111 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFL7 expression at the invasive front
Number of subjects: 230
Study 23922302 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-olaparib chemotherapy
Number of subjects: 89
Study 23922302 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 89
Study 23924069 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous TBI with LOC
Number of subjects: 586
Study 23924069 — intervention group
Group type: COMPARATOR
Intervention: No previous TBI
Number of subjects: 586
Study 23924590 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010/11 seasonal, trivalent influenza vaccine (TIV)
Number of subjects: 55
Study 23924590 — intervention group
Group type: COMPARATOR
Intervention: AS03 adjuvanted H1N1 vaccine
Number of subjects: 55
Study 23924602 — intervention group
Group type: EXPERIMENTAL
Intervention: Exocrine pancreatic insufficiency (EPI) defined by FE-1 concentration <200 μg/g
Number of subjects: 563
Study 23924602 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe exocrine pancreatic insufficiency (EPI) defined by FE-1 concentration <100 μg/g
Number of subjects: 563
Study 23924602 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of steatorrhea
Number of subjects: 563
Study 23924602 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for EPI
Number of subjects: 563
Study 23924639 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy sequencing after cessation of breastfeeding
Number of subjects: 0
Study 23926193 — intervention group
Group type: COMPARATOR
Intervention: Follow-up I (July 2008 to June 2009)
Number of subjects: 11901
Study 23926193 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up II (July 2009 to April 2011) with newer technology
Number of subjects: 11901
Study 23926193 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up II (July 2009 to April 2011)
Number of subjects: 11901
Study 23926234 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D TVUS
Number of subjects: 99
Study 23926234 — intervention group
Group type: COMPARATOR
Intervention: 2D MRI
Number of subjects: 99
Study 23926234 — intervention group
Group type: COMPARATOR
Intervention: 3D MRI
Number of subjects: 99
Study 23928873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 51
Study 23928873 — intervention group
Group type: COMPARATOR
Intervention: Self-reported compliance
Number of subjects: 51
Study 23928873 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall therapeutic effectiveness
Number of subjects: 51
Study 23928873 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation rate
Number of subjects: 51
Study 23929075 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-osmolar 0.1% riboflavin solution
Number of subjects: 18
Study 23929075 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-osmolar 0.1% riboflavin solution
Number of subjects: 18
Study 23929075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet-A irradiation
Number of subjects: 18
Study 23929075 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment monitoring
Number of subjects: 18
Study 23929784 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 50
Study 23929784 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical controls
Number of subjects: 50
Study 23929927 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low calorie ketogenic weight reduction diet with encouragement of exercise
Number of subjects: 6
Study 23929949 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (1.35 × 10(5) PfSPZ), 5 doses
Number of subjects: 40
Study 23929949 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (1.35 × 10(5) PfSPZ), 4 doses
Number of subjects: 40
Study 23929949 — intervention group
Group type: COMPARATOR
Intervention: Nonvaccinated controls
Number of subjects: 40
Study 23930209 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Number of subjects: 16
Study 23930209 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 7.5 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Number of subjects: 16
Study 23930209 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Number of subjects: 16
Study 23932009 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of an uncovered, self-expandable, metal duodenal stent
Number of subjects: 108
Study 23932335 — intervention group
Group type: EXPERIMENTAL
Intervention: Double negative for oestrogen- and progesterone receptors (ER/PR loss)
Number of subjects: 832
Study 23932335 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic expression of all markers
Number of subjects: 832
Study 23932335 — intervention group
Group type: EXPERIMENTAL
Intervention: ER/PR loss in lymph node negative endometrioid tumours
Number of subjects: 832
Study 23932458 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Control Questionnaire (ACQ) administered at 8 visits
Number of subjects: 305
Study 23934126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature DCs transfected with RNAs encoding melanoma antigens (MART1, MAGE-3, gp100, tyrosinase)
Number of subjects: 12
Study 23934126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature DCs transfected with siRNAs targeting the 3 inducible iP subunits (Arm C)
Number of subjects: 12
Study 23934126 — intervention group
Group type: COMPARATOR
Intervention: Mature DCs untransfected (Arm A)
Number of subjects: 12
Study 23934126 — intervention group
Group type: COMPARATOR
Intervention: Mature DCs transfected with control siRNA (Arm B)
Number of subjects: 12
Study 23934268 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical clustering of STIs (chlamydia, gonorrhea, syphilis)
Number of subjects: 0
Study 23934268 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial SaTScan Statistics software
Number of subjects: 0
Study 23936059 — intervention group
Group type: EXPERIMENTAL
Intervention: hQTc in women with Turner syndrome (414.0 ± 25.5 ms)
Number of subjects: 88
Study 23936059 — intervention group
Group type: EXPERIMENTAL
Intervention: hQTc in women with Turner syndrome (416.9 ± 22.6 ms)
Number of subjects: 88
Study 23936059 — intervention group
Group type: EXPERIMENTAL
Intervention: hQTc in women with Turner syndrome (418.2 ± 24.8 ms)
Number of subjects: 88
Study 23936059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in major Long QT syndrome genes (SCN5A and KCNH2)
Number of subjects: 88
Study 23936059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in a minor Long QT syndrome gene (KCNE2)
Number of subjects: 88
Study 23936565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue diagnosed by NS1 antigen positivity
Number of subjects: 1500
Study 23936565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue diagnosed by serology
Number of subjects: 1500
Study 23936565 — intervention group
Group type: EXPERIMENTAL
Intervention: Chikungunya
Number of subjects: 1500
Study 23936565 — intervention group
Group type: EXPERIMENTAL
Intervention: S. Typhi
Number of subjects: 1500
Study 23936565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue-positive cases not clinically diagnosed
Number of subjects: 1500
Study 23938372 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging laparoscopy (S-LPS) before primary debulking surgery (PDS) or neoadjuvant treatment (NACT)
Number of subjects: 300
Study 23939215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Risk Ankle Rule implementation (phases 2 and 3)
Number of subjects: 2151
Study 23939215 — intervention group
Group type: COMPARATOR
Intervention: Control (no interventions)
Number of subjects: 2151
Study 23939215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Risk Ankle Rule (phases 2 and 3)
Number of subjects: 2151
Study 23939283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense ixabepilone (40 mg/m2 every 14 days with granulocyte-colony stimulating factor)
Number of subjects: 42
Study 23939283 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense FEC (5-fluorouracil 600 mg/m2, epirubicin 90 mg/m2, cyclophosphamide 600 mg/m2 every 14 days with granulocyte-colony stimulating factor)
Number of subjects: 42
Study 23939368 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Rapid Test (ORT)
Number of subjects: 497
Study 23939368 — intervention group
Group type: COMPARATOR
Intervention: Enzyme-Linked Immunosorbent Assay (ELISA)
Number of subjects: 497
Study 23939898 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg every 12 h on day 1, followed by 200 mg every 12 h for 3 days)
Number of subjects: 12
Study 23940128 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human PRL (r-hPRL) 60 μg/kg every 12 hours for 17 days
Number of subjects: 1
Study 23940128 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 1
Study 23940282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (PCI-32765)
Number of subjects: 0
Study 23940592 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly individuals with a history of falls
Number of subjects: 161
Study 23940592 — intervention group
Group type: COMPARATOR
Intervention: Elderly non-fallers
Number of subjects: 161
Study 23940729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 142
Study 23941588 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency volumetric thermal ablation (RFVTA)
Number of subjects: 124
Study 23942767 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD)
Number of subjects: 120
Study 23942767 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular dysfunction (MVD)
Number of subjects: 120
Study 23942767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension (PAH)
Number of subjects: 120
Study 23942767 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of two or three disorders
Number of subjects: 120
Study 23942767 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse cutaneous subset, kidney involvement, velocity of tricuspid regurgitation, diabetes mellitus
Number of subjects: 120
Study 23942767 — intervention group
Group type: EXPERIMENTAL
Intervention: MVD and CAD alone or in combination with PAH
Number of subjects: 120
Study 23942857 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 3746
Study 23942857 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3746
Study 23942908 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Number of subjects: 40
Study 23942908 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET
Number of subjects: 40
Study 23942908 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical MRI
Number of subjects: 40
Study 23944301 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial MRI-guided focused ultrasound thalamotomy
Number of subjects: 15
Study 23945372 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger ex vivo capsules in baseline CSF
Number of subjects: 134
Study 23945372 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule size
Number of subjects: 134
Study 23945372 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF capsule shedding
Number of subjects: 134
Study 23947389 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch antipsychotic plus healthy lifestyle education (HLE)
Number of subjects: 132
Study 23947389 — intervention group
Group type: EXPERIMENTAL
Intervention: Add metformin plus healthy lifestyle education (HLE)
Number of subjects: 132
Study 23947389 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle education (HLE) with no medication change
Number of subjects: 132
Study 23947473 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels in the TESRA cohort
Number of subjects: 410
Study 23947473 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels in the ECLIPSE cohort
Number of subjects: 410
Study 23947473 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs2070600
Number of subjects: 410
Study 23947473 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs2071288
Number of subjects: 410
Study 23948110 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug eluting balloon (DEB)
Number of subjects: 1462
Study 23948110 — intervention group
Group type: COMPARATOR
Intervention: Drug eluting stent (DES)
Number of subjects: 1462
Study 23948301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel Node Biopsy (SNB)
Number of subjects: 478
Study 23948301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Axillary Sampling (LAS)
Number of subjects: 478
Study 23948301 — intervention group
Group type: COMPARATOR
Intervention: Blue and/or Hot Nodes (B&/HN)
Number of subjects: 478
Study 23949214 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU HCG daily for 7 days
Number of subjects: 17
Study 23950152 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for mutations in 12 disease genes (IMPDH1, KLHL7, NR2E3, PRPF3/RP18, PRPF31/RP11, PRPF8/RP13, PRPH2/RDS, RHO, RP1, TOPORS, RPGR, RP2) through PCR-based dideoxy sequencing.
Number of subjects: 170
Study 23950152 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for mutations in autosomal genes.
Number of subjects: 170
Study 23950152 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for mutations in X-linked genes.
Number of subjects: 170
Study 23950152 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of distinct mutations.
Number of subjects: 170
Study 23950178 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat in combination with bortezomib and dexamethasone
Number of subjects: 55
Study 23952719 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI patients at 6 months
Number of subjects: 375
Study 23952719 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI patients at 12 months
Number of subjects: 375
Study 23952719 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI patients at 3 months
Number of subjects: 375
Study 23952719 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI patients at 1 year
Number of subjects: 375
Study 23953269 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone (100mg/day titrated to 100mg thrice/day)
Number of subjects: 24
Study 23953882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine (10-20mg/m²/day for 14 days) + Vorinostat (400mg/day)
Number of subjects: 40
Study 23953882 — intervention group
Group type: COMPARATOR
Intervention: Sequential arm (starting on day 14)
Number of subjects: 40
Study 23953988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (iv LCM) at a loading dose of 400 mg over 30 min, followed by a mean maintenance dose of 400 mg per day
Number of subjects: 16
Study 23953988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (iv LCM)
Number of subjects: 16
Study 23954063 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 3489
Study 23954063 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) for ISR
Number of subjects: 3489
Study 23954063 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stent (DES) for ISR
Number of subjects: 3489
Study 23954335 — intervention group
Group type: EXPERIMENTAL
Intervention: Main vessel (MV) stenting
Number of subjects: 2227
Study 23954889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (2.5 mg/d), cyclophosphamide (50 mg every other day), prednisone (50 mg every other day) for 6 cycles, followed by maintenance therapy.
Number of subjects: 69
Study 23955713 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-angiogenic therapy
Number of subjects: 0
Study 23956613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered self-expandable metal stent (WallFlex) for 6 months
Number of subjects: 23
Study 23958335 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based educational intervention consisting of interactive learning activities conducted in workshops based on evidence-based knowledge.
Number of subjects: 0
Study 23958335 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-equivalent control group, details not specified).
Number of subjects: 0